Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

28 May 2021

899.50

-1.40%

US/Institutional business drives earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

STR's 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging markets was offset by subdued sales in other regulated markets on account of COVID-19. In addition to commercial manufacturing of the Sputnik vaccine by Oct'21, STR is building a basket of COVID-related medicines. The...

Strides Pharma Scien.. has an average target of 1085.00 from 1 broker.

Strides Pharma Science Ltd.

06 Feb 2021

899.50

-1.40%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

The other regulated markets grew by 37% YoY with strong growth and market share increase in the UK, Europe and Australia. The company announced the approval to de-merge Stelis Biopharma into a standalone entity and publicly list the entity. We expect a revenue/PAT CAGR of 10%/28% over FY21E-FY23E on the...

Strides Pharma Science Ltd. is trading above its 200 day SMA of 792.1

Strides Pharma Science Ltd.

04 Feb 2021

899.50

-1.40%

Slower US/Africa biz drag down earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR)'s 3QFY21 performance came in below estimates due to the COVID-related impact on the US and Africa biz. Recovery in the Other Regulated (OTR) business was led by healthy volume traction. At the strategic level, STR would de-merge its Biotech business under Stelis Biopharma and intends to list this, thereby unlocking value for shareholders. We cut our earnings estimate by 19%/7%/5% for FY21/FY22/FY23, accounting for weak Flu season related demand in the US and slower offtake of medicines related to Acute therapies in the Africa business. We roll...

Strides Pharma Science Ltd. is trading above its 200 day SMA of 792.1

Strides Pharma Science Ltd.

30 Oct 2020

899.50

-1.40%

2Q - COVID-led aberration hurts performance

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR)'s 2QFY21 performance came in below estimates due to COVID-related a) disruptions at its manufacturing facilities and b) softness in demand in the UK / select European countries. However, the outlook remains positive, with normalcy back in manufacturing operations. We cut our earnings estimate by 10.2%/4.9% for FY21/FY22, factoring in COVID-related disruption in 2QFY21. We value STR on a 12M forward SOTP basis EV/EBITDA of 11x for Regulated segment, 6x for Emerging Markets (EM) segment, and 7x for Institutional segment to arrive at Target Price of...

Promoters unpledged 5.97% of shares in last quarter. Total pledge stands at 44.13% of promoter holdings

Strides Pharma Science Ltd.

29 Oct 2020

899.50

-1.40%

Strides Pharma

Buy: Strides Pharma Science Ltd.

Sharekhan

Q2FY2021 was a soft quarter for Strides. The results missed estimates. Revenues grew 11% YoY to Rs 793 crore while the adjusted PAT at Rs 44 crore declined by 9%. Strtides expects a marked improvement in its performance in 2HFY2021 as compared...

Strides Pharma has lost -43.53% in the last 1 Year

Strides Pharma Science Ltd.

06 Aug 2020

899.50

-1.40%

Strong revival in earnings led by Other Regulated / Africa

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

We roll our price target to INR650 on a 12M forward SOTP basis (8x EV/EBITDA for the US / Other Regulated markets, 6x for Emerging Markets, and 5x for Institutional). Considering this and its increased market share in commercialized products, we expect US sales to revive and exhibit a 6% CAGR to USD270m over STR recorded the highest ever quarterly revenue of INR2.6b in the Other Regulated market, implying growth of 53% on a YoY basis in 1QFY21. We expect the business to exhibit a 23% CAGR in sales to INR12.6b over STR exhibited 17% YoY / 47% QoQ growth in the Emerging Markets business, led by an increase in primary sales in Africa. in Other Regulated and 52% sales CAGR in Emerging Markets, supported by our price target to INR650 on a 12M forward SOTP basis (8x EV/EBITDA for US / Other Regulated, 6x for Emerging Markets, and 5x for Institutional).

Promoters unpledged 5.97% of shares in last quarter. Total pledge stands at 44.13% of promoter holdings

Strides Pharma Science Ltd.

26 May 2020

899.50

-1.40%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

We upgrade our rating to Accumulate based on 10x FY22 EPS with a target of price of Rs.485 as new launches in U.S and other regulated markets will drive growth. Revenues were down 26% yoy and down 16% qoq mainly on...

Number of FII/FPI investors decreased from 287 to 275 in Sep 2025 qtr

Strides Pharma Science Ltd.

17 Mar 2020

899.50

-1.40%

STRIDES PHARMA SCIENCE LIMITED

Hold: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

The U.S sales grew 62% YoY (16% QoQ) during the quarter, with the move to front end sales paying dividends. Other regulated markets saw 54% in YoY growth in revenue, led by...

Number of FII/FPI investors decreased from 287 to 275 in Sep 2025 qtr

Strides Pharma Science Ltd.

30 Jan 2020

899.50

-1.40%

Reset strategy + product-specific opportunity drive earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Further, the company appears set to build biopharma and injectables as new levers of growth over the next 3-4 years. We expect ramp-ups to progress well on the back of new launches and increased traction in existing products. We raise our EPS estimate by 21%/12.6%/8.4% for FY20/21/22 to factor in strong traction in US generics and other regulated markets. Re-iterate led by US business (+62% YoY/16% QoQ to INR4.6b or USD66m) and other regulated markets business (+54% YoY to INR2.2b). However, emerging market sales declined 62% YoY to INR566m. Gross margin (GM) expanded 1,360bp YoY/620bp QoQ to 58.2%, led by a better product mix and partly on a low base of 3QFY19. Accordingly, EBITDA margin improved 420bp QoQ/1,200bp YoY to 24.7% Adj. PAT grew at a higher rate of ~330% (INR794m v/s our est.

Promoters unpledged 5.97% of shares in last quarter. Total pledge stands at 44.13% of promoter holdings

Strides Pharma Science Ltd.

11 Dec 2019

899.50

-1.40%

Biosimilars/Sterile Injectables - new growth levers in the making

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

11 December 2019 After delivering 31% CAGR in US generics revenue over FY17-19, STR appears well positioned to sustain this momentum led by its robust product pipeline (~40 under development/targets to file 20 ANDAs every year) and superior execution in approved products (led by no failure to supply, integrated APIs and cost leadership). The two-pronged strategy of (a) increasing penetration of the already approved products by entering new territories and (b) further building the product portfolio led to strong revenue growth of 67% YoY from other regulated markets in 1HFY20. Healthy order book, opportunities from product shortage (particularly in the UK) and new launches in the EU will provide STR with a good platform to grow business in the other regulated markets over the next 2-3 years (we forecast at least 50% revenue CAGR over the next two years). STR is building multiple levers in the form of a healthy ANDA pipeline and a specialized portfolio of injectables/bio pharma to deliver strong earnings growth over the next 3-4 years.

Strides Pharma Scien.. has an average target of 1085.00 from 1 broker.

Is Strides Pharma Science Ltd. worth buying?

491 Votes:

Buy 78.82%

Sell 11.81%

Hold 9.37%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf